Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

Completed · Phase 2 · Has a placebo group

Conditions studied: Pancreatic Cancer

In brief

The purpose of this study is to determine whether patients with locally advanced pancreatic cancer who receive dasatinib added to standard of care (gemcitabine) live longer, compared to patients who receive standard of care (gemcitabine) plus placebo; i.e. gemcitabine alone.

Key facts

Study ID

NCT01395017

Run by

Otsuka Pharmaceutical Development & Commercialization, Inc.

People needed

202

Starts

2011-06-01

Expected to finish

2015-03-01

Last updated by the study team

2016-04-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologic or cytologic documentation of unresectable adenocarcinoma of the pancreas.
• Recovery from toxicity of previous procedures to establish the diagnosis. ECOG PS 0 or 1.
• Adequate organ function.

You may not qualify if…

• Evidence of metastatic disease.
• Previous radiotherapy or chemoradiotherapy.
• History of or current pleural effusion.
• History of significant cardiovascular disease.
• Clinically significant bleeding disorder or coagulopathy.
• Concomitant medication with strong CYP 3A4 inhibitor.

Where it is running

• Study site — Los Angeles, California, United States
• Study site — Orange, California, United States
• Study site — San Francisco, California, United States
• Study site — Aurora, Colorado, United States
• Study site — Boynton Beach, Florida, United States
• Study site — Tampa, Florida, United States
• Study site — Wichita, Kansas, United States
• Study site — Minneapolis, Minnesota, United States
• Study site — Albuquerque, New Mexico, United States
• Study site — Bethlehem, Pennsylvania, United States
• Study site — Blacktown, New South Wales, Australia
• Study site — Liverpool, New South Wales, Australia
• Study site — Tweed Heads, New South Wales, Australia
• Study site — Footscray, Victoria, Australia
• Study site — Frankston, Victoria, Australia
• Study site — Parkville, Victoria, Australia
• Study site — Vienna, Austria
• Study site — Brussels, Belgium
• Study site — Ghent, Belgium
• Study site — Leuven, Belgium
• Study site — Toronto, Ontario, Canada
• Study site — Toronto, Ontario, Canada
• Study site — Montreal, Quebec, Canada
• Study site — Olomouc, Czechia
• Study site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.